CSP - Certified Specialty Pharmacist Clinical Management: Oncology Questions and Answers — Questions and Answers
Question 1: A patient with metastatic non-small cell lung cancer is being treated with pembrolizumab (Keytruda), an immune checkpoint inhibitor. After several cycles, the patient reports severe, persistent diarrhea (Grade 3 toxicity). According to current clinical guidelines for managing immune-related adverse events (irAEs), what is the MOST appropriate initial action for the specialty pharmacist to recommend?
- Initiate loperamide and continue pembrolizumab at the current dose.
- Administer a dose of infliximab and continue pembrolizumab.
- Hold pembrolizumab and initiate high-dose corticosteroids. (Correct answer)
- Switch to a different immune checkpoint inhibitor, such as nivolumab.
Correct answer: Hold pembrolizumab and initiate high-dose corticosteroids.
For Grade 3 or 4 immune-related adverse events (irAEs) such as severe colitis/diarrhea, standard management guidelines recommend holding or discontinuing the immune checkpoint inhibitor (ICI) and initiating high-dose corticosteroids (e.g., prednisone 1-2 mg/kg/day). Loperamide is insufficient for severe, immune-mediated diarrhea. Infliximab is typically reserved for steroid-refractory cases. Switching to another ICI is not recommended as irAEs are a class effect.
Question 2: A specialty pharmacist is counseling a patient newly diagnosed with Chronic Myeloid Leukemia (CML) who is starting oral imatinib. Which of the following is a critical counseling point to ensure optimal therapeutic outcomes?
- The medication can be taken at any time of day, with or without food.
- Strict adherence to the prescribed regimen is crucial to prevent drug resistance and disease progression. (Correct answer)
- It is safe to take over-the-counter antacids concurrently for stomach upset.
- Missed doses should be doubled up at the next scheduled time to maintain efficacy.
Correct answer: Strict adherence to the prescribed regimen is crucial to prevent drug resistance and disease progression.
Adherence to tyrosine kinase inhibitors (TKIs) like imatinib is paramount for achieving and maintaining response in CML. Non-adherence is strongly correlated with loss of response and disease progression. Imatinib should be taken with a meal and a large glass of water to minimize gastrointestinal irritation. Antacids can decrease absorption and should be spaced out. Doubling up on missed doses is generally not recommended.
Question 3: Which of the following oncology medications requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program with Elements to Assure Safe Use (ETASU) due to its significant teratogenic risk?
- Trastuzumab (Herceptin)
- Rituximab (Rituxan)
- Paclitaxel (Taxol)
- Lenalidomide (Revlimid) (Correct answer)
Correct answer: Lenalidomide (Revlimid)
Lenalidomide (Revlimid) has a well-documented, high risk of severe, life-threatening birth defects and is subject to a strict REMS program. This program includes Elements to Assure Safe Use (ETASU) such as prescriber and pharmacy certification, and mandatory patient registry and pregnancy testing to prevent fetal exposure. The other medications listed do not have REMS programs with such stringent requirements.
Question 4: A specialty pharmacy receives a new prescription for palbociclib (Ibrance) for a patient with HR+, HER2- metastatic breast cancer. The pharmacist notes the patient is also taking ketoconazole, a strong CYP3A4 inhibitor. What is the most appropriate clinical intervention?
- Dispense both medications as prescribed with a warning to monitor for liver toxicity.
- Recommend discontinuing ketoconazole and starting a non-interacting antifungal. (Correct answer)
- Recommend increasing the dose of palbociclib to overcome the interaction.
- Advise the patient to separate the administration times by at least 12 hours.
Correct answer: Recommend discontinuing ketoconazole and starting a non-interacting antifungal.
Palbociclib is a substrate of the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors like ketoconazole can significantly increase palbociclib concentrations and the risk of toxicity, such as neutropenia. The prescribing information recommends avoiding concomitant use. The best intervention is to recommend an alternative agent that does not inhibit CYP3A4. Dose reduction of palbociclib is an option if concomitant use is unavoidable, but switching the interacting agent is preferred.
Question 5: Which of the following is a primary role of a specialty pharmacist in managing patients on oral chemotherapy?
- Performing diagnostic imaging to assess tumor response.
- Administering intravenous supportive care medications in the clinic.
- Proactively monitoring for and managing treatment-related adverse events and adherence. (Correct answer)
- Prescribing the initial oral chemotherapy regimen.
Correct answer: Proactively monitoring for and managing treatment-related adverse events and adherence.
A key function of a specialty pharmacist in oncology is the ongoing management of patients on oral anticancer agents. This includes proactive patient education, monitoring for side effects, managing toxicities, assessing adherence, and communicating with the provider to optimize therapy. Prescribing, administering IV drugs, and ordering imaging are typically outside the pharmacist's scope of practice.
Question 6: A patient receiving chemotherapy for colon cancer develops Grade 2 mucositis. Which of the following interventions would be an appropriate supportive care recommendation from the specialty pharmacist?
- Initiate prophylactic systemic antibiotics.
- Prescribe a potent opioid analgesic like fentanyl.
- Advise a bland, soft diet and a 'magic mouthwash' containing lidocaine. (Correct answer)
- Immediately hold the next cycle of chemotherapy.
Correct answer: Advise a bland, soft diet and a 'magic mouthwash' containing lidocaine.
For Grade 2 mucositis, management focuses on symptomatic relief to maintain oral intake. A bland, soft diet avoids irritation, and topical anesthetics like lidocaine, often part of a 'magic mouthwash' formulation, can relieve pain. Opioids may be needed for severe (Grade 3-4) pain. Systemic antibiotics are not indicated unless there is a secondary infection. Holding chemotherapy is generally reserved for more severe, life-threatening toxicities.
CSP - Certified Specialty Pharmacist Clinical Management: Oncology Questions and Answers
A patient with metastatic non-small cell lung cancer is being treated with pembrolizumab (Keytruda), an immune checkpoint inhibitor.
After several cycles, the patient reports severe, persistent diarrhea (Grade 3 toxicity).
According to current clinical guidelines for managing immune-related adverse events (irAEs), what is the MOST appropriate initial action for the specialty pharmacist to recommend?